share_log

Pfizer | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC(4.96%)

SEC announcement ·  Mar 15 19:50
Summary by Futu AI
Pfizer Inc., a pharmaceutical giant incorporated in Delaware, has filed an exit filing with the United States Securities and Exchange Commission (SEC) on January 29, 2024, indicating that it no longer holds more than 5% of Tourmaline Bio, Inc.'s common stock. The filing, made under Rule 13d-1(c) of the Securities Exchange Act of 1934, shows that Pfizer Inc. beneficially owns 1,272,214 shares of Tourmaline Bio's common stock, which represents 4.96% of the company's class of securities. This percentage is based on 25,645,262 shares of common stock outstanding as disclosed by Tourmaline Bio in its prospectus supplement filed on January 26, 2024. The address of Pfizer's principal business office is 66 Hudson Boulevard East, New York, NY, and the CUSIP number for the securities is 89157D 105. Pfizer's filing confirms that the shares were not acquired for the purpose of changing or influencing the control of Tourmaline Bio and were not held in connection with any transaction having that purpose or effect.
Pfizer Inc., a pharmaceutical giant incorporated in Delaware, has filed an exit filing with the United States Securities and Exchange Commission (SEC) on January 29, 2024, indicating that it no longer holds more than 5% of Tourmaline Bio, Inc.'s common stock. The filing, made under Rule 13d-1(c) of the Securities Exchange Act of 1934, shows that Pfizer Inc. beneficially owns 1,272,214 shares of Tourmaline Bio's common stock, which represents 4.96% of the company's class of securities. This percentage is based on 25,645,262 shares of common stock outstanding as disclosed by Tourmaline Bio in its prospectus supplement filed on January 26, 2024. The address of Pfizer's principal business office is 66 Hudson Boulevard East, New York, NY, and the CUSIP number for the securities is 89157D 105. Pfizer's filing confirms that the shares were not acquired for the purpose of changing or influencing the control of Tourmaline Bio and were not held in connection with any transaction having that purpose or effect.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.